Introduction {#Sec1}
============

Tuberculosis (TB) disease burden remains high in parts of the world^[@CR1],[@CR2]^. A quarter of the world's population has been infected with *M*. *tuberculosis*, of whom a fraction will develop active disease within their lifetime^[@CR1],[@CR2]^. In 2017, 10.0 million incident cases were estimated with TB disease and 1.3 million died from it^[@CR1],[@CR2]^. There is a recognition that major reduction in TB burden is difficult to achieve without controlling its risk factors. The World Health Organization's (WHO) post-2015 TB strategy calls for prioritization of interventions addressing the key TB risk factors including diabetes mellitus (DM)^[@CR3]^.

A synergetic relationship between TB and DM has been suspected for decades^[@CR4]^, but has only recently emerged as a global-health concern, with the growing DM prevalence in TB endemic regions^[@CR5],[@CR6]^, Globally, an estimated 425 million people live with DM; a number that is expected to grow to 629 million by 2045^[@CR7]^. Low- and middle-income countries are the epicenter of the increasing DM burden accounting for over 80% of global DM cases^[@CR7]^.

DM appears to increase the risk of TB disease by about three-fold^[@CR5],[@CR6],[@CR8]^, and to have profound adverse impact on TB-treatment outcomes (e.g. DM appears to increase the risk of TB death by two to four-fold, and TB disease relapse and recurrence by two-fold, among others)^[@CR6],[@CR9]--[@CR13]^. DM is suspected to account for a considerable proportion of TB-disease incident cases^[@CR14]--[@CR21]^, highlighting the importance of the joint TB-DM epidemic. Yet, our understanding of the underlying biological/epidemiological interactions between TB and DM remains limited. It is critical to delineate these complex interactions to assess both the direct and indirect implications of DM on TB's burden^[@CR6],[@CR22]^.

Most indirect implications of TB-DM interactions relate to onward transmission of TB infection. DM may increase the risk of development of TB disease, which is a *direct* (etiological) effect for DM on TB. However, with the ensuing pool of infectious individuals with TB disease, TB transmission would increase leading to more individuals with TB infection. The latter onward-transmission effect is an *indirect* effect of DM increasing the risk of development of TB disease. While conventional population attributable fraction (*PAF*) approaches (such as *Levin's formula*^[@CR23]^) can estimate the direct population impact of DM on TB disease, they do not account for the indirect impacts. The latter, however, can be captured and estimated through mathematical modeling of TB-transmission dynamics in the population.

Against this background, we aimed first to develop a conceptual framework that describes the different possible pathways by which DM could affect TB natural history and treatment outcomes. Second, we translated this conceptual framework into a population-based mathematical TB-DM model incorporating these effects and their *direct* and *indirect* impacts. Third, we assessed the impacts of these effects (using a "flat change" of 300% to standardize the effect size) on TB epidemiology by applying the model in a representative high TB-burden setting. The study thus provides a theoretical analytical investigation of the implications of the DM effects (alone and in combinations) on TB epidemiology for an improved understanding of the TB-DM synergy. Using a standardized effect size also enabled the investigation and comparison of the theoretical importance of both direct and indirect impacts for each potential pathway. The research questions along with the corresponding methods are summarized in Figure [1](#Fig1){ref-type="fig"}. This study approach was deemed necessary as we do not yet have sufficient empirical evidence to quantify the precise and exact effect sizes of most of these DM-on-TB effects. Therefore, our work presents an original and comprehensive theoretical assessment of the potential TB-DM interactions and their implications on TB epidemiology, particularly how important indirect (or true population) effects might be for each pathway. It does not aim to provide precise information on the absolute actual impact of each pathway on TB epidemiology.Figure 1List of the key research questions assessed in this study along with the methods used to address them.

Methods {#Sec2}
=======

Conceptual framework for TB-DM interactions {#Sec3}
-------------------------------------------

We conducted a literature review based on which we developed a conceptual framework of TB-DM interactions. Available publications on the TB-DM interactions were reviewed through searches using the PubMed and Google Scholar databases up to May 2017. For inclusiveness, we used broad search criteria with terms exploded to cover all subheadings. Any publication reporting on TB-DM interactions qualified for inclusion in this review. No language or year restrictions were imposed. The review identified the plausible mechanisms and effects by which DM can influence TB's natural history and treatment outcomes.

Mathematical model, data sources, and model fitting {#Sec4}
---------------------------------------------------

We constructed a population-based dynamical TB-DM mathematical model to represent the developed conceptual framework and assess the direct and indirect impacts of the effects of DM on TB. The model is an adaptation of an earlier TB-transmission model^[@CR24]^ that was extended to include DM and the postulated TB-DM interactions. The model consisted of a system of coupled nonlinear differential equations stratifying the population according to TB infection status and stage, disease form, treatment status, and recovery status.

The model incorporated two TB natural histories depending on DM status (Fig. [2](#Fig2){ref-type="fig"}). DM was parsimoniously included in the model by stratifying a specific and fixed proportion of the population to be living with DM. DM-free individuals were also assumed to be susceptible but at risk of TB infection. Newly infected individuals progress into either latent-slow TB infection (LSI) or latent-fast TB infection (LFI). Individuals with LSI develop TB disease at a rate corresponding to a 5% lifetime risk of developing TB disease^[@CR24]--[@CR27]^---meaning that the risk of developing TB disease is so small that only 5% of individuals in LSI will eventually develop the disease, simply because they would have reached the end of their life expectancy before developing TB disease. Individuals with LFI develop TB disease within a short duration after infection^[@CR24]--[@CR26]^.Figure 2A conceptual framework for the TB-DM epidemiologic synergy. The black lines indicate the transitions within TB's natural history and treatment states. The red lines indicate the 10 plausible effects of DM on TB natural history and treatment outcomes.

TB disease was stratified into three clinically-relevant forms: smear-positive pulmonary (SP-PTB), smear-negative pulmonary (SN-PTB), and extra-pulmonary (EP-TB)^[@CR24],[@CR27]^. Pulmonary TB disease forms were assumed infectious, but at varying levels^[@CR24],[@CR28]^.

Treated individuals without DM proceed to the recovery state in six months reflecting the typical 6-months treatment course under the directly-observed treatment, short course (DOTS)^[@CR29]^. Treated and recovered individuals can be re-exposed to a new TB infection, and subsequently proceed to TB disease.

DM individuals followed a similar TB natural history to that of non-DM individuals, but the natural history was modulated by specific effects of having DM. DM was assumed to affect TB's natural history and treatment outcomes at the different TB stages. Further details on the model can be found in Supplementary Text [S1](#MOESM1){ref-type="media"}.

Model parameters were chosen according to empirical evidence and through model fitting to data. Supplementary Table [S1](#MOESM1){ref-type="media"} lists the parameter values and their sources. Data for India were used to parameterize the country-specific parameters^[@CR30],[@CR31]^. India was chosen as an illustrative example since both TB incidence and DM prevalence are high in this country^[@CR32]^. Note that given that we used arbitrary effect sizes for the interaction effects, this exploratory analysis does not provide estimates of the population impact of DM on TB in India.

The model was fitted to TB-incidence (i.e. 217 per 100,000 population per year), mortality (i.e. 39 per 100,000 population per year), and case fatality (i.e. 0.17) rates for the year 2015, as obtained from the WHO's Global Health Observatory data repository^[@CR30]^; and to national DM prevalence (i.e. 8.6%) for the year 2015, as obtained from the International Diabetes Federation^[@CR31]^. Three country-specific parameters were derived by model fitting to data: respiratory contact rate, TB case detection rate, and DM-related mortality rate.

The population size was held constant to disentangle the TB-DM epidemiological effects from the demographic effects. All analyses were conducted assuming endemic equilibrium for TB. The model was coded and analyzed in MATLAB R2015a^[@CR33]^.

Epidemiologic implications of TB-DM interactions {#Sec5}
------------------------------------------------

Using the model, we assessed the implications of each of the plausible/potential DM effects on TB epidemiology, individually and in combinations. For a standardized comparison of the impact across the different mechanisms, we assumed a flat change of 300% for each pathway by which DM affects TB; that is, a standard effect size (ES) of 3.0 for each mechanism with an expected ES ≥1, and (an inverse) ES of 1/3 for each mechanism with an ES \<1. This specific choice of ES value is relevant but otherwise arbitrary, as we aimed to assess the impact given a specific standardized ES for all DM-on-TB effects. This value of ES of 3.0 was deemed reasonable given the strength of the observed association (for different but closely-related statistical measures) between TB and DM in systematic reviews and meta-analyses^[@CR5],[@CR6],[@CR8]^. Noting that, for most effects, the ES as estimated in the literature was heterogeneous in value, had only suggestive evidence with no assessed value, or could not be disentangled from the ES of another effect. While we used an ES of 3.0 for each effect, our model is general and can assess theoretically the impact of any combination of ESs.

We assessed the TB-DM epidemiologic synergy using two population-level measures: incidence hazard ratio (HR) and "true" population attributable fraction (*PAF*~*True*~). The HR was defined as the ratio of TB disease incidence rates among those with DM over those with no DM, within the same population (Equation 2.1 of Supplementary Text [S1](#MOESM1){ref-type="media"}).

The *PAF*~*True*~ was assessed for three TB-disease outcome measures: incidence, prevalence, and mortality. For each, it was defined as the proportional reduction in the measure in a comparison between the measure in a scenario where there is TB-DM epidemiologic synergy (some active effects for DM on TB), compared to a counter-factual scenario where there is no TB-DM epidemiologic synergy (no active effect; Equation 2.2 of Supplementary Text [S1](#MOESM1){ref-type="media"}). These two scenarios were simulated using the model by assuming an ES of 3.0 (or 1/3) in the epidemiologic-synergy scenario, and an ES of 1.0 in the no-epidemiologic-synergy scenario. This approach for assessing the *PAF* is labeled as "true" *PAF*^[@CR34],[@CR35]^, because it captures the *direct* (etiological) effects of DM on TB, as well as the *indirect* (such as onward transmission) effects of DM on TB.

In addition to *PAF*~*True*~, we estimated the *PAF* using the conventional but simplistic *Levin's formula* (*PAF*~*Levin*~)^[@CR23]^, which cannot capture the indirect effects, for comparison purposes (Equation 2.3 of Supplementary Text [S1](#MOESM1){ref-type="media"}). Strictly speaking, we assessed the *PAF*~*Levin*~ for only the specific situation that it applies: assuming that DM increases the risk of developing TB disease by a factor of 3 (relative risk (*RR*) = 3), based on existing estimates^[@CR5],[@CR6],[@CR8]^ and not on a specific DM-on-TB effect.

Results {#Sec6}
=======

Conceptual framework for TB-DM interactions {#Sec7}
-------------------------------------------

Figure [2](#Fig2){ref-type="fig"} illustrates the conceptual framework of TB-DM interactions that was developed based on the evidence gleaned from the literature review, for epidemiologically-relevant effects with either robust or suggestive evidence. DM was accordingly postulated to affect TB's natural history and treatment outcomes in 10 different potential ways. Each of these was labeled as "effect" and numbered accordingly. A description of each effect and citations to its supporting evidence can be found in Table [1](#Tab1){ref-type="table"}. Of notice that the strength of the evidence based varied for each effect, and quite often was either potentially biased, or estimated with wide confidence intervals.Table 1The plausible effects of diabetes mellitus (DM) on tuberculosis (TB) natural history and treatment outcomes.EffectDescriptionStatistical measure of effect as incorporated in the modelExpected range based on available evidenceSources**Effects of DM on TB's natural history (TB infection and/or TB disease)***Effect 1-Susceptibility*DM increases the susceptibility to TB infectionHazard ratio≥1^[@CR36]--\ [@CR40]^*Effect 2-Fast progression*DM increases the proportion of TB infections entering latent-fast state as opposed to latent-slow stateProportion ratio≥1[@CR5],[@CR8],[@CR10],[@CR42]--[@CR48]*Effect 3-Reactivation*DM increases the rate of developing TB disease among those with latent TB infectionRate ratio≥1^[@CR5],\ [@CR8],\ [@CR10],\ [@CR42]--\ [@CR48]^*Effect 4-Latent reinfection*DM increases the susceptibility to TB reinfection among those with latent-slow TB infectionHazard ratio≥1^[@CR5],\ [@CR8],\ [@CR10],\ [@CR42]--\ [@CR48]^*Effect 5-Smear positivity*DM increases the proportion of new PTB^\#^ disease cases progressing to SP-PTB\* as opposed to SN-PTB^\$^Proportion ratio≥1^[@CR51]--\ [@CR60]^*Effect 6-Disease infectiousness*DM increases the infectiousness of PTB (SP-PTB and SN-PTB) for both untreated and treated TB disease casesFactor ratio≥1^[@CR51],\ [@CR54],\ [@CR61],\ [@CR62]^*Effect 7-TB mortality*DM increases the hazard of TB-related mortality for both untreated and treated TB disease casesHazard ratio≥1^[@CR12],\ [@CR52],\ [@CR53],\ [@CR60],\ [@CR61],\ [@CR63]^**Effects of DM on TB treatment outcomes***Effect 8-Treatment failure*DM reduces the proportion of successful treatment (through increased risk of treatment failure and MDR-TB^¥^)Proportion ratio≥1^[@CR12],\ [@CR57],\ [@CR64]^*Effect 9-Recovery*DM reduces the rate of TB recovery (i.e. prolongs the recovery time) for those who recover naturally or due to treatmentRate ratio≥1^[@CR51],\ [@CR54],\ [@CR55],\ [@CR64]--\ [@CR67]^*Effect 10-Cured reinfection*DM increases the susceptibility to TB reinfection among those treated or recovered from TB diseaseHazard ratio≥1^[@CR12],\ [@CR64]\#^PTB: Pulmonary TB; \*SP-PTB: smear-positive pulmonary TB; ^\$^SN-PTB: smear-negative pulmonary TB; ^¥^MDR-TB: multi-drug resistant TB.

There was evidence suggesting that DM may increase *susceptibility to TB infection* (*Effect 1-Susceptibility*)^[@CR36]--[@CR41]^---an effect to be distinguished from that of increasing *susceptibility to TB disease*.

Ample evidence supported an increased risk of developing TB disease for those with DM^[@CR5],[@CR8],[@CR10],[@CR42]--[@CR50]^. However, this evidence did not differentiate the precise biological mechanism of whether DM is associated with increased proportion of TB infections entering the LFI state, as opposed to the LSI state (*Effect 2-Fast progression)*; increased susceptibility to develop TB disease among those with LSI (*Effect 3-Reactivation*); and/or increased susceptibility to TB reinfection among those with LSI (*Effect 4-Primary reinfection*).

Several studies indicated that DM increases the proportion of developing SP-PTB disease (as opposed to SN-PTB) among those who progress to pulmonary TB disease (*Effect 5-Smear positivity*)^[@CR51]--[@CR60]^. DM was also found to be a risk factor for increased *M*. *tuberculosis* bacterial load^[@CR51],[@CR54],[@CR61],[@CR62]^; a proxy biomarker for increased TB infectiousness among those with pulmonary TB disease (*Effect 6-Disease infectiousness*)---that is, DM increasing the risk of TB transmission per one respiratory contact as a consequence of the higher bacterial load.

Strong evidence indicated that DM increases the risk of TB-related mortality among treated TB-disease individuals (*Effect 7-TB mortality*)^[@CR12],[@CR13],[@CR52],[@CR53],[@CR60],[@CR61],[@CR63]^. We assumed, given biological plausibility, that the same effect applies for untreated TB disease individuals (*Effect 7-TB mortality*).

Several studies indicated that DM reduces the proportion of successful treatment among those undergoing TB treatment (through increased risk of treatment failure and multi-drug resistant TB; *Effect 8-Treatment failure*)^[@CR12],[@CR13],[@CR57],[@CR64]^. Also, recent studies demonstrated a greater risk of persisting TB smear or sputum culture positivity by the second to third month of treatment, delaying the resolution of TB disease among those with DM compared to those without DM (*Effect 9-Recovery*)^[@CR51],[@CR54],[@CR55],[@CR64]--[@CR67]^.

Evidence indicated an increased susceptibility to TB reinfection after TB treatment and recovery among those with DM (*Effect 10-Cured reinfection*)^[@CR12],[@CR13],[@CR64]^. Cured reinfection is defined as a subsequent episode of TB disease in a TB patient who received at least six months of TB treatment, but developed active TB after successful treatment (i.e. smear or sputum culture was negative at the end of the treatment period). Given biological plausibility, we assumed that the same effect applies to naturally recovered individuals.

All these effects were incorporated in the conceptual framework, and in the TB-DM mathematical model, as delineated in Equation 2.2 of Supplementary Text [S1](#MOESM1){ref-type="media"}.

Impact of TB-DM interactions on the hazard ratio of TB disease {#Sec8}
--------------------------------------------------------------

Figure [3A](#Fig3){ref-type="fig"} shows the model-estimated HRs for the 10 TB-DM effects. The standardized ES of 3.0 (or 1/3) for each effect impacted the HR differently. *Effect 2-Fast progression* had the largest impact with an HR of 2.7, which is within the range found in observational studies^[@CR8]^. *Effect 3-Reactivation*, *Effect 1*-*Susceptibility*, and *Effect 4*-*Latent reinfection* had an intermediate HR impact in the range of 1.3--1.4, which is also within the range found in observational studies^[@CR8]^. *Effect 10-Cured reinfection* had a minor HR impact of 1.1, which is outside the range found in observational studies^[@CR8]^. For the remaining effects (*Effect* 5-*Smear positivity*, *Effect 6-Disease infectiousness*, *Effect 7-TB mortality*, *Effect 8-Treatment failure*, and *Effect 9-Recovery*), the HR was 1.0---these effects had no impact on the HR, which is also outside the range found in observational studies^[@CR8]^.Figure 3Epidemiological impact of the 10 plausible effects of diabetes mellitus (DM) on tuberculosis (TB) natural history and treatment outcomes, as measured by the incidence hazard ratio (HR) of TB disease among those with DM compared to those without DM. (**A**) Results of the impact of each of the effects individually. (**B**) Results of the impact of all possible combinations of the effects that individually had an HR \>1.0. Each DM on TB effect had a standardized effect size (ES) of 3.0 if the expected ES (based on evidence) is ≥1, and (an inverse) ES of 1/3 if the expected ES is \<1 (red line).

By assessing all possible effect combinations (for those with HR \>1.0), the HR ranged between 1.4 (*Effect 3-Reactivation* and *Effect 10-Cured reinfection*) and 7.8 (combining all effects; Fig. [3B](#Fig3){ref-type="fig"}). Every combination that included *Effect 2-Fast progression* reached an HR of 3.0 or higher, but none of the combinations that did not include *Effect 2-Fast progression* reached an HR of 3.0 or higher.

By assessing all possible pairwise combinations for all effects, the HR ranged between 1.0 (for several pairwise combinations) and 3.8 (*Effect 2-Fast progression* and *Effect 4*-*Latent reinfection*; Supplementary Fig. [S1A](#MOESM1){ref-type="media"}). Few of the pairwise combinations that included *Effect 2-Fast progression* reached an HR of 3.0 or higher, but none of the combinations that did not include *Effect 2-Fast progression* reached an HR of 3.0 or higher.

Variation in the effect size of each of the DM-on-TB effects and observed HR {#Sec9}
----------------------------------------------------------------------------

In an additional one-way sensitivity analysis, the ES of each of the DM-on-TB effects was varied to yield the observed HR of 3.0 (Fig. [4](#Fig4){ref-type="fig"}). For *Effect 1*-*Susceptibility*, *Effect* 5-*Smear positivity*, *Effect 6-Disease infectiousness*, *Effect 7-TB mortality*, *Effect 8-Treatment failure*, *Effect 9-Recovery*, and *Effect 10-Cured reinfection*, no value for the ES would yield an HR value of 3.0. However, for *Effect 2-Fast progression*, *Effect 3-Reactivation*, and *Effect 4*-*Latent reinfection* a value of 3.4, 24.0, and 12.0, respectively, would yield an HR value of 3.0. Moreover, the ranking of the impact on HR of the DM-on-TB effects barely changed regardless of the ES, appart from a minor change in the ranking of *Effect 1-Susceptibility*, mainly due to the saturation of the impact of this effect on the HR (Fig. [4](#Fig4){ref-type="fig"}). The sensitivity of the model output to changes in TB fast progression has been also observed in a previous modelling study^[@CR68]^.Figure 4Assessment of varying the effect size of each of the diabetes mellitus (DM) on tuberculosis (TB) effects to yield the observed hazard ratio (HR) of 3.0. HR is defined as the ratio of TB disease incidence rate among those with DM compared to those without DM.

The epidemiological impact of varying simultaneously the ES (from 1.5 to 5.0) of all pairwise combinations of the effects that individually had an HR \>1.0 (for an ES of 3.0) was assessed in an additional sensitivity analysis (Fig. [S3](#MOESM1){ref-type="media"}). For ES less than 4.0, the ranking of the impact on HR for the DM-on-TB effects was unchanged. However, for higher ES, there was one main change in the ranking; the scale of the HR for the combination of *Effect 2-Fast progression* and *Effect 10-Cured reinfection* became higher than other combinations, highlighting the importance of their synergy, possibly related to surpassing the reinfection threshold^[@CR69]--[@CR72]^.

Impact of TB-DM interactions on the population attributable fractions {#Sec10}
---------------------------------------------------------------------

Figure [5A](#Fig5){ref-type="fig"} shows the proportion of TB-disease incidence attributed directly or indirectly (i.e. *PAF*~*True*~) to DM for the 10 TB-DM effects assuming a standardized ES of 3.0 (or 1/3). *PAF*~*True*~ for TB-disease incidence ranged between −4.6% (*Effect 7-TB mortality*) and 34.5% (*Effect 2-Fast progression*). The second largest *PAF*~*True*~ at 29.9% was for *Effect 6-Disease infectiousness* (DM increasing TB infectiousness by three-fold). The lowest *positive PAF*~*True*~ at 1.3% was for *Effect* 5-*Smear positivity*.Figure 5Proportion of tuberculosis (TB) disease incidence (**A**), prevalence (**B**), and mortality (**C**) attributed to each of the effects of diabetes mellitus (DM) on TB natural history and treatment outcomes. These population attributable fraction (*PAF*~*True*~) measures were estimated as the proportional reduction in the measure in a comparison between the measure in a scenario where there is TB-DM epidemiologic synergy (that is some effect for DM on TB is active), compared to a counter-factual scenario where there is no TB-DM epidemiologic synergy. Each DM on TB effect had a standardized effect size (ES) of 3.0 if the expected ES (based on evidence) is ≥1, and (an inverse) ES of 1/3 if the expected ES is \<1. The red bar (and line) in panel **A** is the estimated *Levin's formula* population attributable fraction, assuming a relative risk (*RR*) of 3.0 for TB-disease incidence among DM versus non-DM individuals.

Of notice, the impact of *Effect 5-Smear positivity* and *Effect 6-Disease infectiousness* on TB transmission dynamics were different, despite the apparent similarity in mechanism of action. *Effect 6-Disease infectiousness* increased TB transmission in the population by increasing the risk of TB transmission for a given infectious contact. While *Effect 5-Smear positivity* also led to increased TB transmission in the population by increasing the pool of smear-positive TB cases, this effect was undermined by the fact that smear-positive TB cases had a higher risk of TB mortality (Supplementary Table [S1](#MOESM1){ref-type="media"}).

The effect of DM on TB mortality (*Effect 7-TB mortality*) caused a negative *PAF*~*True*~ of −4.6%, as the higher mortality of individuals with TB-DM reduced TB transmission in the population, and thus TB disease incidence (i.e. TB-DM individuals died before spreading the infection further).

The predicted impact of DM on TB-disease incidence using *Levin's formula* (assuming that DM increases the risk of developing TB disease by three-fold) was estimated at 14.7% (Fig. [5A](#Fig5){ref-type="fig"}). The latter should be seen as a baseline for comparison of the different impacts.

Figure [5B](#Fig5){ref-type="fig"} shows the proportion of TB-disease prevalence attributed to DM for the 10 effects, assuming similary ES of 3.0 (or 1/3). The impact of each effect on TB-disease prevalence was overall similar to that on TB-disease incidence (Fig. [5B](#Fig5){ref-type="fig"}). The proportion of TB-disease prevalence attributed to each effect ranged between −7.1% (*Effect 7-TB mortality*) and 34.5% (*Effect 2-Fast progression*).

Figure [5C](#Fig5){ref-type="fig"} shows the proportion of TB-disease mortality attributed to DM for the 10 effects, assuming similary ES of 3.0 (or 1/3). The pattern was overall similar to that for TB-disease incidence and prevalence. The proportion of TB-disease mortality attributed to each effect ranged between 0.9% (*Effect* 5-*Smear positivity*) and 34.5% (*Effect 2-Fast progression*). The effect on TB mortality (*Effect 7-TB mortality*) caused here a *positive* impact of 5.4%, versus the *negative* impacts on TB-disease incidence (−4.6%) and prevalence (−7.1%).

Supplementary Figure [S1](#MOESM1){ref-type="media"} shows the results for *PAF*~*True*~ for all possible combinations of the five effects that individually had the largest *PAF*~*True*~. The proportion of TB-disease incidence attributed to DM ranged between 22.5% (*Effect 1-Susceptibility* and *Effect 4-Latent reinfection*) and 89.1% (combining all effects). By assessing all possible pairwise combinations for all effects, the *PAF*~*True*~ for incidence ranged between −3.5% (*Effect 7-TB mortality* and *Effect 10-Cured reinfection*) and 70.9% (*Effect 2-Fast progression* and *Effect 6-Disease infectiousness*; Supplementary Fig. [S2B](#MOESM1){ref-type="media"}).

Table [2](#Tab2){ref-type="table"} shows a comparison of the impact of DM on TB-disease incidence as measured by *PAF*~*True*~ and HR. *Effect 2-Fast progression* had the highest impact using both measures. There were some effects that had large impact on *PAF*~*True*~, but limited or no impact on HR, most notably *Effect 6-Disease infectiousness* that had the second largest *PAF*~*True*~.Table 2The epidemiologic implications\* of each of the plausible diabetes mellitus (DM) effects on tuberculosis (TB) natural history and treatment outcomes as measured by the "true" population attributable fraction (*PAF*~*True*~) and incidence hazard ratio (HR).Effect^\#^*PAF* ~*True*~HR*Effect 2-Fast progression*34.5%2.7*Effect 6-Disease infectiousness*29.9%1.0*Effect 8-Treatment failure*14.8%1.0*Effect 4-Latent reinfection*11.1%1.4*Effect 1-Susceptibility*9.9%1.4*Effect 3-Reactivation*8.2%1.3*Effect 9-Recovery*3.8%1.0*Effect 10-Cured reinfection*1.7%1.1*Effect 5-Smear positivity*1.3%1.0*Effect 7-TB mortality*−4.6%1.0If no effect of DM on TB0.0%1.0Relevant reference measure14.7%^\$^3.0^€\#^Effects are ordered from largest to lowest *PAF*. ^\$^*PAF* estimated using *Levin's formula*^[@CR23]^. ^€^Typical effect size using different, but closely-related statistical measures (such as hazard ratio, relative risk, rate ratio, and odds ratio) of the strength of the observed TB-DM association^[@CR5],[@CR6],[@CR8]^.\*We assumed a standard effect size of 3.0 for each mechanism with an expected effect size ≥1 and (an inverse) effect size of 1/3 for each mechanism with an effect size ≤1.

Discussion {#Sec11}
==========

We investigated the mechanisms by which DM can affect TB natural history and treatment outcomes, and therefore can impact TB-transmission dynamics. Seven epidemiologically-relevant plausible effects for DM on TB natural history, and three for DM on TB treatment outcomes, were identified based on literature review. Informed by this empirical evidence, we developed a conceptual framework of DM's effects on TB (Fig. [2](#Fig2){ref-type="fig"}), and translated it into a mathematical model to investigate the impact of these effects on TB-transmission dynamics. Our main findings show that conventional estimates of the *PAF* (that is using *Levin's formula*) indicate that 15% of TB-disease incidence is attributable to DM (in India where the model was applied for *Effect 2-Fast progression*; Fig. [5A](#Fig5){ref-type="fig"}), but taking into account indirect effects (onward transmission), the "true" *PAF* could be two-fold higher at 35%. The "true" *PAF*, however, depends on which DM-on-TB effect (or combination of effects) is assumed to be active; looking at each listed pathway individually and assuming a standardized ES of 3.0 (or 1/3) yielded a "true" *PAF* that ranged from −5% to 35% (Fig. [5](#Fig5){ref-type="fig"}).

Although the 10 effects impacted TB-transmission dynamics (Fig. [5](#Fig5){ref-type="fig"}), the impact (for several of them) could not be captured by the HR (Fig. [3A](#Fig3){ref-type="fig"})---the conventional epidemiologic measure of the TB-DM association. The reason is that the HR captures only the effects of DM on *directly developing TB disease*, but cannot capture effects that leads *indirectly* to more TB disease in the population. For example, evidence suggests a higher TB infectiousness with DM (*Effect 6-Disease infectiousness*), because of higher *M*. *tuberculosis* bacterial load^[@CR51],[@CR54],[@CR61],[@CR62]^. The higher infectiousness contributes to more TB transmission in the population, but this effect cannot be captured by a study that compares TB incidence among those with DM to those without DM (conventional cohort or case-control studies)---the higher infectiousness affects *both comparison groups simultaneously*.

Of the 10 investigated effects, only four resulted in an impact that could be actually measured by the HR (Fig. [3A](#Fig3){ref-type="fig"}). Even though the ES of each effect was standardized at 3.0, all effects had an HR \<3; the HR was not a representative measure of the *true* ES of each effect. *Effect 2-Fast progression* resulted in the largest HR at 2.7, while *Effect 3-Reactivation*, *Effect 1*-*Susceptibility*, and *Effect 4*-*Latent reinfection* had HRs of only about 1.4. Also, based on the comparison between the measured HR assuming the standard ES of 3.0 and the actual pooled evidence for the TB-DM assosciation, including prospective (3.59, 95% confidence interval \[CI\] 2.25--5.73), retrospective (1.55, 95% CI 1.39--1.72), and case-control studies (2.09, 95% CI 1.71--2.55); it seems that only *Effect 1*-*Susceptibility*, *Effect 2-Fast progression*, *Effect 3-Reactivation*, and *Effect 4*-*Latent reinfection* can explain the TB-DM assosiation.

It is possible that the 10 TB-DM effects could be acting simultanously, and therefore their individual impacts on the HR are difficult (if not impossible) to disentangle. Figure [4](#Fig4){ref-type="fig"} highlights that some pathways are impossible to result in an HR of 3.0 by themselves (i.e. *Effect 1*-*Susceptibility*, *Effect* 5-*Smear positivity*, *Effect 6-Disease infectiousness*, *Effect 7-TB mortality*, *Effect 8-Treatment failure*, *Effect 9-Recovery*, and *Effect 10-Cured reinfection*), while other pathways can reach an HR of 3.0 by themselves but only at very high effect sizes (i.e. effect size of 24 and 12 for *Effect 3-Reactivation* and *Effect 4*-*Latent reinfection*, respectively).

The measured HR in an epidemiological study may reflect thus the *combined* effect of several individual effects (Fig. [3B](#Fig3){ref-type="fig"} and Supplementary Fig. [S2A](#MOESM1){ref-type="media"}). For instance, by combining *Effect 2-Fast progression* and *Effect 3-Reactivation*, the HR of 3.0 (suggested by the recently updated systematic review^[@CR7]^) can be easily reached (Fig. [3B](#Fig3){ref-type="fig"} and Supplementary Fig. [4](#MOESM1){ref-type="media"}). Indeed, some combinations that included *Effect 2-Fast progression* reached an HR of 3.0 or higher, but none of the combinations that did not include *Effect 2-Fast progression* reached an HR of 3.0 or higher. Even for some of the effects that alone did not have an HR \>1 (e.g. *Effect 6-Disease infectiousness*, *Effect 7-TB mortality*, and *Effect 8-Treatment failure*), by combining them with *Effect 2-Fast progression* an HR higher than the HR of *Effect 2-Fast progression* alone was reached, higlighting synergy in combining these effects (Supplementary Fig. [S2A](#MOESM1){ref-type="media"}). Supplementary Figure [S3](#MOESM1){ref-type="media"} also highlights the potential synergy in combining effects, and shows that the impact (i.e. ranking/importance) of some of the pairwise combinations of the TB-on-DM effects on HR may change at large values for the ES (here larger than 4.0).

These findings highlight how the focus on measures such as HR, relative risk, rate ratio, and odds ratio, to assess the TB-DM association, can be misleading. These measures cannot capture the actual impact of some TB-DM effects which influence TB epidemiology indirectly---the focus on such measures may be preventing us from appreciating the extent to which DM is influencing TB-transmission dynamics.

We found that the impact of DM on TB is better assessed using the "true" *PAF* (*PAF*~*True*~) as it captures both the direct and indirect impacts, and for all 10 effects. Taking *Effect 6-Disease infectiousness* (that had an HR = 1.0; Fig. [3A](#Fig3){ref-type="fig"}) as an example, 30% of TB-disease incidence was attributed to this effect (assuming three-fold increased TB infectiousness with DM; Fig. [5A](#Fig5){ref-type="fig"}). This large impact arises not only from the *direct* enhanced TB transmission from those with concurrent DM, but also from the *indirect* onward transmission with the larger pool of infected persons in the population.

Of all effects, assuming a standard ES, *Effect 2-Fast progression* had the largest impact (Fig. [5](#Fig5){ref-type="fig"}). This effect increases TB-disease incidence by increasing the fraction of infections that progress rapidly to TB disease (*direct impact*), but also increases (*indirect impact*) the onward transmission and circulation of TB among both DM and non-DM persons. It is striking that the indirect impact was comparable in scale to the direct impact. This can be seen by comparing the *PAF*~*True*~ of 35% to that of *PAF*~*Levin*~ of only 15% (the latter measures only the direct impact on incidence). These findings further demonstrate how the conventional approach to assess the *PAF* due to DM using *PAF*~*Levin*~^[@CR14],[@CR17]--[@CR21]^, could be underestimating the extent to which DM is influencing TB-transmission dynamics. This, however, will depend on which of the DM-on-TB effects (or combination of effects) is assumed active, as each effect may impact TB transmission dynamics differently, with *PAF*~*True*~ ranging from −5% to 35% (Fig. [5](#Fig5){ref-type="fig"}).

Though only two effects had large *PAF*~*True*~, most effects had small *PAF*~*True*~ (Fig. [5](#Fig5){ref-type="fig"}). The combined effect, however, even of small effects, can add up to a substantial impact (Supplementary Fig. [S1](#MOESM1){ref-type="media"}). If several of the 10 effects (large and small) are present and acting simultanously, the impact of DM on TB could be substantially higher than expected (Fig. [5](#Fig5){ref-type="fig"} and Supplementary Fig. [S2B](#MOESM1){ref-type="media"}). This highlights the need to ascertain the exact ES of each effect, and suggests that DM could be impacting TB epidemiology to a larger extent than previously thought.

Our study has limitations. We included the plausible TB-DM effects based on a literature review, but we may have overlooked effects, particularly if they are not yet supported by evidence. Though there is evidence supporting each considered effect, the evidence is not conclusive for most, and the ES is either imprecise or poorly known. We did not include all factors that may influence the incorporated DM-on-TB effects, or the factors that may affect directly each of TB or DM burdens individually^[@CR8],[@CR63],[@CR73],[@CR74]^. For example, we did not incorporate the impact of using anti-DM medications^[@CR75]--[@CR77]^, or HIV as a co-factor^[@CR63],[@CR73],[@CR74]^. However, in India (as in other parts of the world) a large proportion of people living with DM are undiagnosed and may have uncontrolled DM^[@CR8],[@CR78]--[@CR80]^. Moreover, even for those diagnosed with DM, a proportion of them may not be adhering to anti-DM medications^[@CR81]^. Despite the potential public health implications, prevalence of HIV is relatively low in India at less than 1.0%^[@CR82]^, a fact that is true for nearly all TB-DM burdened countries outside Africa^[@CR83]^, hence, minimally affecting our results and conclusions.

We modeled TB's natural history based on the canonical approach in the literature^[@CR24],[@CR84]^, but TB has a complex natural history that is still far from being settled^[@CR68],[@CR85]^. We assessed the TB-DM epidemiologic synergy assuming endemic and stable levels for TB and DM, with no assessment of the implications of the temporal-dynamics and time-varying infectivity profile. The DM-on-TB effects were assumed constant with time, but the fluctuating blood glucose levels in individuals with DM may affect the stability of the rates as assumed in this model. The model did not include the varying age-stratification for DM, but DM is strongly age-dependent. Bearing these limitations in mind, the aim of the present analysis was to assess the epidemiological implications of the TB-DM interactions from a theoretical perspective that focuses on the core interaction effects, and avoids entanglement with demographic and temporal effects. Thus, we resorted to a parsimonious model structure where DM is included as a fixed proportion of the population and with temporally-invariable DM-on-TB effects, thereby presenting an "average" impact of DM on TB rather than a full temporally-varying impact.

We did not explicitly factor multi-drug resistant TB (MDR TB) and the effect of DM on MDR TB in the model. However, \<5% of newly treated TB cases globally are estimated to have MDR TB^[@CR86]^, and thus this is not likely to affect our results. We did not factor the effect of intermediate hyperglycemia (pre-DM) on TB, leading to plausible underestimation of DM's impact on TB. We focused on the effects of DM on TB, but the links between the two diseases could be bi-directional^[@CR46]^, thereby further complicating analyses of their epidemiologic synergy.

In conclusion, we provided a conceptual mapping of how DM affects TB natural history and treatment outcomes through 10 plausible effects, and investigated the epidemiological impact of each effect on TB-transmission dynamics. We used a standardized ES for each effect though in reality each may vary with implications on the HR and the *PAF*. The ESs of these effects are yet to be established with precision, and therefore we cannot determine nor draw specific conclusions about the exact and total impact of DM on TB in India. Several effects could not be assessed using conventional epidemiologic-study designs of the TB-DM association, and therefore their impact may have been overlooked in existing literature. The impact of DM on TB should be assessed using a *PAF*~*True*~ approach, as the one presented here, since this approach can capture the combined direct and indirect impacts of each effect. Thus, the unique contribution of our paper is to highlight the potentially large indirect (true population) effects associated with some pathways, particularly if DM's effects on TB are dominated by rapid TB progression or increased infectiousness.

We found that the indirect impact on TB-transmission dynamics (e.g. onward transmission) of some of the effects is large and comparable to the direct impact. Even for effects with small impacts, the combined effect of several could be substantial. While the impact of several effects on the HR was limited, the impact on the *PAF* was substantial suggesting that DM could be impacting TB epidemiology to a larger extent than previously thought. They also stress the need to assess with precision the ESs of these effects to determine the actual total impact of DM on TB. A better understanding of the TB-DM epidemiologic synergy is critical to improved control and preventive strategies for TB disease burden, and to achieving the goal of TB elimination by 2050.
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